Thomas Woiwode - Net Worth and Insider Trading

Thomas Woiwode Net Worth

The estimated net worth of Thomas Woiwode is at least $151 Million dollars as of 2024-11-10. Thomas Woiwode is the Director of Audentes Therapeutics Inc and owns about 1,806,832 shares of Audentes Therapeutics Inc (BOLD) stock worth over $108 Million. Thomas Woiwode is the Director of CRISPR Therapeutics AG and owns about 645,643 shares of CRISPR Therapeutics AG (CRSP) stock worth over $33 Million. Thomas Woiwode is also the Director, 10% Owner of Tempest Therapeutics Inc and owns about 4,295,055 shares of Tempest Therapeutics Inc (TPST) stock worth over $5 Million. Besides these, Thomas Woiwode also holds Passage Bio Inc (PASG) , Aligos Therapeutics Inc (ALGS) , Gritstone Bio Inc (GRTSQ) . Details can be seen in Thomas Woiwode's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Thomas Woiwode has not made any transactions after 2022-04-29 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Thomas Woiwode

Thomas Woiwode Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Thomas Woiwode owns 7 companies in total, including Aligos Therapeutics Inc (ALGS) , Adverum Biotechnologies Inc (ADVM) , and Gritstone Bio Inc (GRTSQ) among others .

Click here to see the complete history of Thomas Woiwode’s form 4 insider trades.

Insider Ownership Summary of Thomas Woiwode

Ticker	Comapny	Transaction Date	Type of Owner
ALGS	Aligos Therapeutics Inc	2021-04-26	director
ADVM	Adverum Biotechnologies Inc	2020-12-14	director
GRTSQ	Gritstone Bio Inc	2020-12-30	director
		2020-03-03	director & 10 percent owner
		2018-05-15	director
		2016-08-24	director
		2022-04-29	director & 10 percent owner

Thomas Woiwode Latest Holdings Summary

Thomas Woiwode currently owns a total of 6 stocks. Among these stocks, Thomas Woiwode owns 1,806,832 shares of Audentes Therapeutics Inc (BOLD) as of July 25, 2016, with a value of $108 Million and a weighting of 71.84%. Thomas Woiwode owns 645,643 shares of CRISPR Therapeutics AG (CRSP) as of May 15, 2018, with a value of $33 Million and a weighting of 22.08%. Thomas Woiwode also owns 4,295,055 shares of Tempest Therapeutics Inc (TPST) as of April 29, 2022, with a value of $5 Million and a weighting of 3.1%. The other 3 stocks Passage Bio Inc (PASG) , Aligos Therapeutics Inc (ALGS) , Gritstone Bio Inc (GRTSQ) have a combined weighting of 2.98% among all his current holdings.

Latest Holdings of Thomas Woiwode

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
BOLD	Audentes Therapeutics Inc	2016-07-25	1,806,832	59.97	108,355,715
CRSP	CRISPR Therapeutics AG	2018-05-15	645,643	51.59	33,308,722
TPST	Tempest Therapeutics Inc	2022-04-29	4,295,055	1.09	4,681,610
PASG	Passage Bio Inc	2020-03-03	4,959,769	0.61	3,040,338
ALGS	Aligos Therapeutics Inc	2020-10-20	131,694	10.19	1,341,962
GRTSQ	Gritstone Bio Inc	2020-12-30	4,450,638	0.03	111,266

Holding Weightings of Thomas Woiwode

Thomas Woiwode Form 4 Trading Tracker

According to the SEC Form 4 filings, Thomas Woiwode has made a total of 0 transactions in Audentes Therapeutics Inc (BOLD) over the past 5 years. The most-recent trade in Audentes Therapeutics Inc is the acquisition of 35,000 shares on July 25, 2016, which cost Thomas Woiwode around $525,000.

According to the SEC Form 4 filings, Thomas Woiwode has made a total of 0 transactions in CRISPR Therapeutics AG (CRSP) over the past 5 years. The most-recent trade in CRISPR Therapeutics AG is the sale of 44,000 shares on May 15, 2018, which brought Thomas Woiwode around $3 Million.

According to the SEC Form 4 filings, Thomas Woiwode has made a total of 1 transactions in Tempest Therapeutics Inc (TPST) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Tempest Therapeutics Inc is the acquisition of 2,118,644 shares on April 29, 2022, which cost Thomas Woiwode around $5 Million.

More details on Thomas Woiwode's insider transactions can be found in the Insider Trading History of Thomas Woiwode table.

Insider Trading History of Thomas Woiwode

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Thomas Woiwode Trading Performance

GuruFocus tracks the stock performance after each of Thomas Woiwode's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Thomas Woiwode is 51.65%. GuruFocus also compares Thomas Woiwode's trading performance to market benchmark return within the same time period. The performance of stocks bought by Thomas Woiwode within 3 months outperforms 5 times out of 6 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Thomas Woiwode's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Thomas Woiwode

Average Return

Average return per transaction

Outperforming Transactions

4 out of 6 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	63.64
Relative Return to S&P 500(%)	65.47

Thomas Woiwode Ownership Network

Ownership Network List of Thomas Woiwode

No Data

Ownership Network Relation of Thomas Woiwode

Thomas Woiwode Owned Company Details

What does Aligos Therapeutics Inc do?

Who are the key executives at Aligos Therapeutics Inc?

Thomas Woiwode is the director of Aligos Therapeutics Inc. Other key executives at Aligos Therapeutics Inc include 10 percent owner Roche Holding Ltd , 10 percent owner Roche Finance Ltd , and Chief Medical Officer Matthew W. Mcclure .

Aligos Therapeutics Inc (ALGS) Insider Trades Summary

Over the past 18 months, Thomas Woiwode made no insider transaction in Aligos Therapeutics Inc (ALGS). Other recent insider transactions involving Aligos Therapeutics Inc (ALGS) include a net purchase of 7,933,601 shares made by Carole Nuechterlein ,

In summary, during the past 3 months, insiders sold 0 shares of Aligos Therapeutics Inc (ALGS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aligos Therapeutics Inc (ALGS) were sold and 317,344 shares were bought by its insiders, resulting in a net purchase of 317,344 shares.

Aligos Therapeutics Inc (ALGS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aligos Therapeutics Inc Insider Transactions

No Available Data

What does Adverum Biotechnologies Inc do?

Who are the key executives at Adverum Biotechnologies Inc?

Thomas Woiwode is the director of Adverum Biotechnologies Inc. Other key executives at Adverum Biotechnologies Inc include Chief Development Officer Setareh Seyedkazemi , Chief Financial Officer Linda M Rubinstein , and Chief Scientific Officer Brigit Riley .

Adverum Biotechnologies Inc (ADVM) Insider Trades Summary

Over the past 18 months, Thomas Woiwode made no insider transaction in Adverum Biotechnologies Inc (ADVM). Other recent insider transactions involving Adverum Biotechnologies Inc (ADVM) include a net purchase of 302,064 shares made by Braden Michael Leonard , a net purchase of 130,000 shares made by Lupher, Jr. Mark L. , and a net purchase of 100,000 shares made by Linda M Rubinstein .

In summary, during the past 3 months, insiders sold 0 shares of Adverum Biotechnologies Inc (ADVM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 620 shares of Adverum Biotechnologies Inc (ADVM) were sold and 335,064 shares were bought by its insiders, resulting in a net purchase of 334,444 shares.

Adverum Biotechnologies Inc (ADVM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Adverum Biotechnologies Inc Insider Transactions

No Available Data

What does Gritstone Bio Inc do?

Who are the key executives at Gritstone Bio Inc?

Thomas Woiwode is the director of Gritstone Bio Inc. Other key executives at Gritstone Bio Inc include director & President and CEO Andrew R Allen , See Remarks Matthew Hawryluk , and See Remarks Karin Jooss .

Gritstone Bio Inc (GRTSQ) Insider Trades Summary

Over the past 18 months, Thomas Woiwode made no insider transaction in Gritstone Bio Inc (GRTSQ). Other recent insider transactions involving Gritstone Bio Inc (GRTSQ) include a net sale of 1,749 shares made by Vassiliki Economides , a net sale of 24,263 shares made by Andrew R Allen , and a net sale of 13,749 shares made by Erin Jones .

In summary, during the past 3 months, insiders sold 0 shares of Gritstone Bio Inc (GRTSQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 74,769 shares of Gritstone Bio Inc (GRTSQ) were sold and 12,000 shares were bought by its insiders, resulting in a net sale of 62,769 shares.

Gritstone Bio Inc (GRTSQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Gritstone Bio Inc Insider Transactions

No Available Data

What does Passage Bio Inc do?

Who are the key executives at Passage Bio Inc?

Thomas Woiwode is the director & 10 percent owner of Passage Bio Inc. Other key executives at Passage Bio Inc include 10 percent owner Orbimed Advisors Llc , SVP & Interim CFO Kathleen Borthwick , and Chief Medical Officer Mark S Forman .

Passage Bio Inc (PASG) Insider Trades Summary

Over the past 18 months, Thomas Woiwode made no insider transaction in Passage Bio Inc (PASG). Other recent insider transactions involving Passage Bio Inc (PASG) include a net purchase of 953,146 shares made by Orbimed Advisors Llc , a net sale of 11,453 shares made by Simona King , and a net sale of 4,052 shares made by Alexandros Fotopoulos .

In summary, during the past 3 months, insiders sold 239,431 shares of Passage Bio Inc (PASG) in total and bought 0 shares, with a net sale of 239,431 shares. During the past 18 months, 258,044 shares of Passage Bio Inc (PASG) were sold and 1,192,577 shares were bought by its insiders, resulting in a net purchase of 934,533 shares.

Passage Bio Inc (PASG)'s detailed insider trading history can be found in Insider Trading Tracker table.

Passage Bio Inc Insider Transactions

No Available Data

What does CRISPR Therapeutics AG do?

Who are the key executives at CRISPR Therapeutics AG?

Thomas Woiwode is the director of CRISPR Therapeutics AG. Other key executives at CRISPR Therapeutics AG include Chief Business Officer Samarth Kulkarni , General Counsel and Secretary James R. Kasinger , and Chief Financial Officer Raju Prasad .

CRISPR Therapeutics AG (CRSP) Insider Trades Summary

Over the past 18 months, Thomas Woiwode made no insider transaction in CRISPR Therapeutics AG (CRSP). Other recent insider transactions involving CRISPR Therapeutics AG (CRSP) include a net sale of 179,630 shares made by Samarth Kulkarni , a net sale of 6,949 shares made by James R. Kasinger , and a net sale of 3,524 shares made by Raju Prasad .

In summary, during the past 3 months, insiders sold 5,382 shares of CRISPR Therapeutics AG (CRSP) in total and bought 0 shares, with a net sale of 5,382 shares. During the past 18 months, 193,469 shares of CRISPR Therapeutics AG (CRSP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 193,469 shares.

CRISPR Therapeutics AG (CRSP)'s detailed insider trading history can be found in Insider Trading Tracker table.

CRISPR Therapeutics AG Insider Transactions

No Available Data

What does Audentes Therapeutics Inc do?

Who are the key executives at Audentes Therapeutics Inc?

Thomas Woiwode is the director of Audentes Therapeutics Inc. Other key executives at Audentes Therapeutics Inc include President and COO Natalie C. Holles , SVP & Chief Medical Officer Edward R. Conner , and Executive Vice President & CFO Thomas P Soloway .

Audentes Therapeutics Inc (BOLD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Audentes Therapeutics Inc (BOLD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Audentes Therapeutics Inc (BOLD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Audentes Therapeutics Inc (BOLD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Audentes Therapeutics Inc Insider Transactions

No Available Data

What does Tempest Therapeutics Inc do?

Who are the key executives at Tempest Therapeutics Inc?

Thomas Woiwode is the director & 10 percent owner of Tempest Therapeutics Inc. Other key executives at Tempest Therapeutics Inc include 10 percent owner Versant Venture Capital Vi, L.p. , director & Chief Executive Officer Stephen R Brady , and Chief Medical Officer Samuel Whiting .

Tempest Therapeutics Inc (TPST) Insider Trades Summary

Over the past 18 months, Thomas Woiwode made no insider transaction in Tempest Therapeutics Inc (TPST). Other recent insider transactions involving Tempest Therapeutics Inc (TPST) include a net sale of 787,999 shares made by Versant Venture Capital Vi, L.p. , a net purchase of 35,000 shares made by Stephen R Brady , and a net purchase of 4,672 shares made by Samuel Whiting .

In summary, during the past 3 months, insiders sold 787,999 shares of Tempest Therapeutics Inc (TPST) in total and bought 0 shares, with a net sale of 787,999 shares. During the past 18 months, 787,999 shares of Tempest Therapeutics Inc (TPST) were sold and 39,672 shares were bought by its insiders, resulting in a net sale of 748,327 shares.

Tempest Therapeutics Inc (TPST)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tempest Therapeutics Inc Insider Transactions

No Available Data

Thomas Woiwode Mailing Address

Above is the net worth, insider trading, and ownership report for Thomas Woiwode. You might contact Thomas Woiwode via mailing address: One Sansome Street, Suite 1650, San Francisco Ca 94104.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.